Ani Pharmaceuticals (ANIP) Change in Receivables (2012 - 2026)

Ani Pharmaceuticals has reported Change in Receivables for 15 years, with the latest figure at -$25.5 million in Q1 2026.

• Quarterly Change in Receivables fell 1332.55% year-over-year to -$25.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.8 million (up 287.95% YoY) and the FY2025 annual result came in at $58.5 million, up 177.56% from the prior year.
• Change in Receivables declined to -$25.5 million in Q1 2026 per ANIP's latest filing, from $27.9 million in the prior quarter.
• Over five years, Change in Receivables peaked at $27.9 million in Q4 2025 and troughed at -$25.5 million in Q1 2026.
• A 5-year average of $5.2 million and a median of $5.5 million in 2025 frame the typical range for Change in Receivables.
• The sharpest annual moves came in 2022 and 2026: Change in Receivables jumped 2333.29% in 2022, then slumped 1332.55% in 2026.
• Over 5 years, Change in Receivables stood at $25.0 million in 2022, then sank by 167.04% to -$16.8 million in 2023, then soared by 252.2% to $25.5 million in 2024, then advanced by 9.18% to $27.9 million in 2025, then tumbled by 191.64% to -$25.5 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered -$25.5 million, $27.9 million, and $27.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.